Piper Sandler Maintains Overweight on Gilead Sciences, Maintains $95 Price Target
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Joseph Catanzaro has reiterated an Overweight rating for Gilead Sciences, maintaining a price target of $95.
September 11, 2024 | 1:55 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler has reiterated an Overweight rating for Gilead Sciences, maintaining a price target of $95, indicating confidence in the company's stock performance.
The reaffirmation of an Overweight rating and a $95 price target by Piper Sandler suggests a positive outlook for Gilead Sciences. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100